Abstract #0761
Evaluation of chemoresistance on human GBM by amide proton transfer (APT) imaging in mice
Masaya Takahashi 1,2 , Koji Sagiyama 1 , Osamu Togao 1 , Tomoyuki Mashimo 3,4 , Shanrong Zhang 1 , Vamsidhara Vemireddy 4,5 , Kimmo J. Hatanpaa 6 , Elizabeth A. Maher 3,4 , A. Dean Sherry 1,2 , and Robert M. Bachoo 4,5
1
Advanced Imaging Research Center, University
of Texas Southwestern Medical Center, Dallas, Texas,
United States,
2
Radiology,
University of Texas Southwestern Medical Center, Dallas,
Texas, United States,
3
Internal
Medicine, University of Texas Southwestern Medical
Center, Dallas, Texas, United States,
4
Harold
C. Simmons Comprehensive Cancer Center, University of
Texas Southwestern Medical Center, Dallas, Texas, United
States,
5
Neurology,
University of Texas Southwestern Medical Center, Dallas,
Texas, United States,
6
Pathology,
University of Texas Southwestern Medical Center, Dallas,
Texas, United States
Amide proton transfer (APT) imaging shows increasing
interest in characterization of the brain tumor. The
objective of our study is to investigate whether APT
imaging can provide useful biomarker to determine
treatment responses or resistance of the glioblastoma
multiforme (GBM) in chemotherapy. In the present study,
we compared two human GBM cell lines derived from the
same patient that have same genotype, which is a unique
and powerful system to compare directly the APT signal
in the setting of temozolomide sensitivity and
resistance.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
